Outcome measures, case definition, and nomenclature are all important and distinct aspects of atopic eczema: A call for harmonization

Journal of Investigative Dermatology

Volumn 132, Issue 2, 2012, Pages 473-474

  Schmitt, Jochen ^a   Flohr, Carsten ^b   Williams, Hywel C ^c  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FILAGGRIN;

ATOPIC DERMATITIS; CASE DEFINITION; CASE STUDY; GENE MUTATION; HUMAN; LETTER; NOMENCLATURE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SKIN SENSITIZATION; STANDARDIZATION;

EID: 84855938696     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2011.294     Document Type: Letter

References (14)

1. Brenninkmeijer EE, Spuls PI, Legierse CM et al. (2008) Clinical differences between atopic and atopiform dermatitis. J Am Acad Derma-tol 58:407-14 (Pubitemid 351226310)
2. Flohr C, Johansson SG, Wahlgren CF et al. (2004) How atopic is atopic dermatitis? J Allergy Clin Immunol 114:150-8 (Pubitemid 39005132)
3. Flohr C, Weiland SK, Weinmayr G et al. (2008) The role of atopic sensitization in flexural eczema: findings from the International Study of Asthma and Allergies in Childhood Phase Two. J Allergy Clin Immunol 121: 141-7
4. Hanifin JM (2011) Atopic dermatitis nomenclature variants can impede harmonization. J Invest Dermatol. (this issue)
5. Johansson SG, Bieber T, Dahl R et al. (2004) Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 113:832-6 (Pubitemid 38608590)
6. Rodriguez E, Baurecht H, Herberich E et al. (2009) Meta-analysis of filaggrin polymorphisms in eczema and asthma: robust risk factors in atopic disease. J Allergy Clin Immunol 123: 1361-70
7. Schmitt J, Langan S, Stamm T et al. (2011) Core outcome domains for controlled trials and clinical recordkeeping in eczema: international multiperspective Delphi consensus process. J Invest Dermatol 131: 623-30
8. Schmitt J, Williams HC (2010) Harmonising Outcome Measures for Eczema (HOME). Report from the first international consensus meeting (HOME 1), 24 July 2010, Munich, Germany. Br J Dermatol 163:1166-8
9. Sinha I, Jones L, Smyth RL et al. (2008) A systematic review of studies that aim to determine which outcomes to measure in clinical trials in children. PLoS Med 5:e96
10. Sinha IP, Williamson PR, Smyth RL (2009) Outcomes in clinical trials of inhaled corticoster-oids for children with asthma are narrowly focussed on short term disease activity. PLoS One 4:e6276
11. Tugwell P, Boers M (1993) Developing consensus on preliminary core efficacy endpoints for rheumatoid arthritis clinical trials. OMERACT Committee. J Rheumatol 20:555-6 (Pubitemid 23102492)
12. Williams H, Flohr C (2006) How epidemiology has challenged 3 prevailing concepts about atopic dermatitis. J Allergy Clin Immunol 118:209-13 (Pubitemid 43949587)
13. Williams HC (2000) What is atopic dermatitis and how should it be defined in epidemio-logical studies? In: Williams HC (ed) Atopic Dermatitis, Cambridge University Press: Cambridge, 3-24
14. Wuthrich B, Schmid-Grendelmeier P (2003) The atopic eczema/dermatitis syndrome. Epidemiology, natural course, and immunology of the IgE-associated ("extrinsic") and the non-allergic ("intrinsic") AEDS. J Investig Allergol Clin Immunol 13:1-5 (Pubitemid 36781516)